Ipsen reveals promising results from a Phase IIIb/IV ENGAGE trial
Category: #health  By Mateen Dalal  Date: 2019-09-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ipsen reveals promising results from a Phase IIIb/IV ENGAGE trial

limb spasticity is a disorder that hampers the movement of the arms by stiffing the muscles. Spasticity is a result of the body’s damaged nervous system, which generally occurs due to disease, injury or stroke. Several pharma companies have started to develop novel treatments to treat this condition, via clinical trials.

Ipsen is one such pharmaceutical company that has recently announced its initial findings from the ENGAGE trials which claims that the concurrent treatment of Dysport for both lower and upper limb spasticity in adult patients with a GSC (Guided Self-rehabilitation Contract) showed encouraging results, with better voluntary movement as measured by a CXA (composite active range of motion) outcome.

According to reliable sources, the findings from the trial will be shown at the MDS International Congress in France. Moreover, ENGAGE is first study that investigates treatment with Dysport in patients with spastic hemiparesis in both lower and upper limbs accompanied with GSC.

Speaking on the announcement, Professor Jean-Michel Gracies, Primary investigator for ENGAGE and the Chair in the Department of Neurorehabilitation, Henri Mondor Hospital, said that the study offers understanding into treatment that can progress the results of patients suffering from spastic paresis, particularly the part of GSC fused with Dysport for the development of voluntary movement.

Moreover, longer time to reinjection and stronger active motion improvements were witnessed in ENGAGE compared to earlier Dysport studies which indicate a synergistic effect of combining a GSC intervention to treatment with Dysport for patients with upper limb and lower limb spasticity, cites Gracies.

Prior to this recent advancement, Ipsen had made headlines by entering into an agreement to acquire Clementia Pharmaceuticals, a clinical-stage company focusing on developing treatments for people with ultra-rare bone disorders and other diseases with unmet clinical needs.

Reports cite that the deal included Ipsen acquiring Clementia’s investigational RARy (retinoic acid receptor gamma) selective agonist, for the treatment of FOP (fibrodysplasia ossificans progressive), late-stage clinical asset palovarotene, multiple osteochondromas (MO) and several other diseases.

Moreover, the acquisition was intended to leverage Clementia’s expertise in order to strengthen its Rare Disease portfolio with an hope to offer cutting-edge treatments to patients who have high medical needs.

Source Credit: https://www.ipsen.com/press-releases/6619/#

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...